Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 159 participants.

Also called NCT02919059

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 159 participants (planned count) (from the registry)
Sponsor
IInstituto Gallego de Medicina Vascular (from the registry)
Registry
  • NCT NCT02919059
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02919059. Randomized; double masking; primary purpose treatment. Start 2016-12-13 (actual); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dapagliflozin 10 mg
Intervention (Drug)
Glimepiride 4 mg
Lead sponsor
IInstituto Gallego de Medicina Vascular (class: other)

Record details

Record id
cardio:ct-nct02919059
Content hash
d954ac699a58c3afab96b736a6b6047e8a3de975b9226126eb9cccf4750d5cef